|  | eICU (N=2573) | MIMIC (N=4546) | Overall (N=7119) |
| --- | --- | --- | --- |
| **In-hospital Mortality** |  |  |  |
| Died | 1,884 (73.2%) | 3,023 (66.5%) | 4,907 (68.9%) |
| Survived | 689 (26.8%) | 1,523 (33.5%) | 2,212 (31.1%) |
| **90-days Mortality** |  |  |  |
| Died | 0 (0%) | 2,374 (52.2%) | 2,374 (33.3%) |
| Survived | 0 (0%) | 2,172 (47.8%) | 2,172 (30.5%) |
| **Mechanic Ventilation** |  |  |  |
| Received | 1,693 (65.8%) | 2,659 (58.5%) | 4,352 (61.1%) |
| Not received | 880 (34.2%) | 1,887 (41.5%) | 2,767 (38.9%) |
| **Renal Replacement Therapy** |  |  |  |
| Received | 2,415 (93.9%) | 4,172 (91.8%) | 6,587 (92.5%) |
| Did not receive | 158 (6.1%) | 374 (8.2%) | 532 (7.5%) |
| **Vasopressor(s)** |  |  |  |
| Received | 1,389 (54.0%) | 2,471 (54.4%) | 3,860 (54.2%) |
| Not received | 1,184 (46.0%) | 2,075 (45.6%) | 3,259 (45.8%) |
| **Age by group (years)** |  |  |  |
| 18 - 44 | 151 (5.9%) | 256 (5.6%) | 407 (5.7%) |
| 45 - 64 | 893 (34.7%) | 1,678 (36.9%) | 2,571 (36.1%) |
| 65 - 74 | 774 (30.1%) | 1,229 (27.0%) | 2,003 (28.1%) |
| 75 - 84 | 575 (22.3%) | 976 (21.5%) | 1,551 (21.8%) |
| 85 and higher | 180 (7.0%) | 407 (9.0%) | 587 (8.2%) |
| **Age overall (years)** |  |  |  |
| Mean (SD) | 66.6 (13.0) | 66.7 (13.4) | 66.7 (13.3) |
| Median [Min, Max] | 68.0 [19.0, 91.0] | 67.0 [19.0, 91.0] | 67.0 [19.0, 91.0] |
| **Sex** |  |  |  |
| Female | 1,458 (56.7%) | 2,754 (60.6%) | 4,212 (59.2%) |
| Male | 1,115 (43.3%) | 1,792 (39.4%) | 2,907 (40.8%) |
| **Race** |  |  |  |
| Asian | 41 (1.6%) | 193 (4.2%) | 234 (3.3%) |
| Black | 259 (10.1%) | 433 (9.5%) | 692 (9.7%) |
| Hispanic | 172 (6.7%) | 137 (3.0%) | 309 (4.3%) |
| Other | 105 (4.1%) | 531 (11.7%) | 636 (8.9%) |
| White | 1,996 (77.6%) | 3,252 (71.5%) | 5,248 (73.7%) |
| **SOFA Ranges** |  |  |  |
| 0 - 3 | 1,033 (40.1%) | 1,200 (26.4%) | 2,233 (31.4%) |
| 4 - 6 | 903 (35.1%) | 1,641 (36.1%) | 2,544 (35.7%) |
| 7 - 10 | 471 (18.3%) | 1,152 (25.3%) | 1,623 (22.8%) |
| 11 and above | 166 (6.5%) | 553 (12.2%) | 719 (10.1%) |
| **SOFA continuous** |  |  |  |
| Mean (SD) | 4.76 (3.26) | 6.06 (3.57) | 5.59 (3.52) |
| Median [Min, Max] | 4.00 [0, 20.0] | 5.00 [0, 22.0] | 5.00 [0, 22.0] |
| **CCI Ranges** |  |  |  |
| 0 - 3 | 506 (19.7%) | 155 (3.4%) | 661 (9.3%) |
| 4 - 6 | 850 (33.0%) | 884 (19.4%) | 1,734 (24.4%) |
| 7 - 10 | 771 (30.0%) | 2,361 (51.9%) | 3,132 (44.0%) |
| 11 and above | 446 (17.3%) | 1,146 (25.2%) | 1,592 (22.4%) |
| **Charlson Comorbidity Index continuous (CCI)** |  |  |  |
| Mean (SD) | 6.76 (3.58) | 8.67 (2.92) | 7.98 (3.30) |
| Median [Min, Max] | 6.00 [0, 19.0] | 9.00 [0, 20.0] | 8.00 [0, 20.0] |
| **Full Code upon Admission** |  |  |  |
| Not Full Code | 318 (12.4%) | 394 (8.7%) | 712 (10.0%) |
| Full Code | 2,255 (87.6%) | 4,152 (91.3%) | 6,407 (90.0%) |
| **Full Code upon Discharge** |  |  |  |
| Not Full Code | 925 (36.0%) | 577 (12.7%) | 1,502 (21.1%) |
| Full Code | 1,648 (64.0%) | 3,969 (87.3%) | 5,617 (78.9%) |
| **Solid Cancer** |  |  |  |
| Not Present | 714 (27.7%) | 1,531 (33.7%) | 2,245 (31.5%) |
| Present | 1,859 (72.3%) | 3,015 (66.3%) | 4,874 (68.5%) |
| **Hematological Cancer** |  |  |  |
| Not Present | 1,961 (76.2%) | 4,546 (100%) | 6,507 (91.4%) |
| Present | 612 (23.8%) | 0 (0%) | 612 (8.6%) |
| **Metastasized Cancer** |  |  |  |
| Not Present | 2,115 (82.2%) | 2,798 (61.5%) | 4,913 (69.0%) |
| Present | 458 (17.8%) | 1,748 (38.5%) | 2,206 (31.0%) |
| **Colon and Rectal (combined)** |  |  |  |
| Not Present | 2,313 (89.9%) | 4,292 (94.4%) | 6,605 (92.8%) |
| Present | 260 (10.1%) | 254 (5.6%) | 514 (7.2%) |
| **Liver and intrahepatic BD** |  |  |  |
| Not Present | 2,534 (98.5%) | 4,156 (91.4%) | 6,690 (94.0%) |
| Present | 39 (1.5%) | 390 (8.6%) | 429 (6.0%) |
| **Pancreatic** |  |  |  |
| Not Present | 2,498 (97.1%) | 4,272 (94.0%) | 6,770 (95.1%) |
| Present | 75 (2.9%) | 274 (6.0%) | 349 (4.9%) |
| **Lung (including bronchus)** |  |  |  |
| Not Present | 1,996 (77.6%) | 3,867 (85.1%) | 5,863 (82.4%) |
| Present | 577 (22.4%) | 679 (14.9%) | 1,256 (17.6%) |
| **Melanoma** |  |  |  |
| Not Present | 2,542 (98.8%) | 4,514 (99.3%) | 7,056 (99.1%) |
| Present | 31 (1.2%) | 32 (0.7%) | 63 (0.9%) |
| **Breast** |  |  |  |
| Not Present | 2,465 (95.8%) | 4,443 (97.7%) | 6,908 (97.0%) |
| Present | 108 (4.2%) | 103 (2.3%) | 211 (3.0%) |
| **Endometrial** |  |  |  |
| Not Present | 2,505 (97.4%) | 4,489 (98.7%) | 6,994 (98.2%) |
| Present | 68 (2.6%) | 57 (1.3%) | 125 (1.8%) |
| **Prostate** |  |  |  |
| Not Present | 2,414 (93.8%) | 4,305 (94.7%) | 6,719 (94.4%) |
| Present | 159 (6.2%) | 241 (5.3%) | 400 (5.6%) |
| **Kidney** |  |  |  |
| Not Present | 2,508 (97.5%) | 4,421 (97.3%) | 6,929 (97.3%) |
| Present | 65 (2.5%) | 125 (2.7%) | 190 (2.7%) |
| **Bladder** |  |  |  |
| Not Present | 2,487 (96.7%) | 4,429 (97.4%) | 6,916 (97.1%) |
| Present | 86 (3.3%) | 117 (2.6%) | 203 (2.9%) |
| **Thyroid** |  |  |  |
| Not Present | 2,563 (99.6%) | 4,524 (99.5%) | 7,087 (99.6%) |
| Present | 10 (0.4%) | 22 (0.5%) | 32 (0.4%) |
| **NHL** |  |  |  |
| Not Present | 2,402 (93.4%) | 4,159 (91.5%) | 6,561 (92.2%) |
| Present | 171 (6.6%) | 387 (8.5%) | 558 (7.8%) |
| **Leukemia** |  |  |  |
| Not Present | 2,293 (89.1%) | 4,107 (90.3%) | 6,400 (89.9%) |
| Present | 280 (10.9%) | 439 (9.7%) | 719 (10.1%) |
| **Hypertension** |  |  |  |
| Hypertension absent | 1,170 (45.5%) | 1,793 (39.4%) | 2,963 (41.6%) |
| Hypertension present | 1,403 (54.5%) | 2,753 (60.6%) | 4,156 (58.4%) |
| **Heart Failure** |  |  |  |
| CHF absent | 2,112 (82.1%) | 3,333 (73.3%) | 5,445 (76.5%) |
| CHF present | 461 (17.9%) | 1,213 (26.7%) | 1,674 (23.5%) |
| **Asthma** |  |  |  |
| Asthma absent | 2,410 (93.7%) | 4,494 (98.9%) | 6,904 (97.0%) |
| Asthma present | 163 (6.3%) | 52 (1.1%) | 215 (3.0%) |
| **COPD** |  |  |  |
| COPD absent | 1,914 (74.4%) | 3,433 (75.5%) | 5,347 (75.1%) |
| COPD present | 659 (25.6%) | 1,113 (24.5%) | 1,772 (24.9%) |
| **CKD** |  |  |  |
| CKD absent | 2,231 (86.7%) | 4,037 (88.8%) | 6,268 (88.0%) |
| CKD Stage 1 | 2 (0.1%) | 3 (0.1%) | 5 (0.1%) |
| CKD Stage 2 | 141 (5.5%) | 17 (0.4%) | 158 (2.2%) |
| CKD Stage 3 | 83 (3.2%) | 242 (5.3%) | 325 (4.6%) |
| CKD Stage 4 | 16 (0.6%) | 70 (1.5%) | 86 (1.2%) |
| CKD Stage 5 | 100 (3.9%) | 177 (3.9%) | 277 (3.9%) |